Literature DB >> 31576334

Extended follow-up on KEYNOTE-024 suggests significant survival benefit for pembrolizumab in patients with PD-L1 ≥50%, but unanswered questions remain.

Jose M Pacheco1, Dexiang Gao2, D Ross Camidge1.   

Abstract

Entities:  

Year:  2019        PMID： 31576334      PMCID： PMC6685853          DOI： 10.21037/atm.2019.05.72

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  22 in total

Review 1.  Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC.

Authors:  D Ross Camidge; Robert C Doebele; Keith M Kerr
Journal:  Nat Rev Clin Oncol       Date:  2019-06       Impact factor: 66.675

2.  Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.

Authors:  Roy S Herbst; Paul Baas; Dong-Wan Kim; Enriqueta Felip; José L Pérez-Gracia; Ji-Youn Han; Julian Molina; Joo-Hang Kim; Catherine Dubos Arvis; Myung-Ju Ahn; Margarita Majem; Mary J Fidler; Gilberto de Castro; Marcelo Garrido; Gregory M Lubiniecki; Yue Shentu; Ellie Im; Marisa Dolled-Filhart; Edward B Garon
Journal:  Lancet       Date:  2015-12-19       Impact factor: 79.321

3.  Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.

Authors:  Joan H Schiller; David Harrington; Chandra P Belani; Corey Langer; Alan Sandler; James Krook; Junming Zhu; David H Johnson
Journal:  N Engl J Med       Date:  2002-01-10       Impact factor: 91.245

4.  PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project.

Authors:  Fred R Hirsch; Abigail McElhinny; Dave Stanforth; James Ranger-Moore; Malinka Jansson; Karina Kulangara; William Richardson; Penny Towne; Debra Hanks; Bharathi Vennapusa; Amita Mistry; Rasika Kalamegham; Steve Averbuch; James Novotny; Eric Rubin; Kenneth Emancipator; Ian McCaffery; J Andrew Williams; Jill Walker; John Longshore; Ming Sound Tsao; Keith M Kerr
Journal:  J Thorac Oncol       Date:  2016-11-29       Impact factor: 15.609

5.  Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer.

Authors:  Luis Paz-Ares; Alexander Luft; David Vicente; Ali Tafreshi; Mahmut Gümüş; Julien Mazières; Barbara Hermes; Filiz Çay Şenler; Tibor Csőszi; Andrea Fülöp; Jerónimo Rodríguez-Cid; Jonathan Wilson; Shunichi Sugawara; Terufumi Kato; Ki Hyeong Lee; Ying Cheng; Silvia Novello; Balazs Halmos; Xiaodong Li; Gregory M Lubiniecki; Bilal Piperdi; Dariusz M Kowalski
Journal:  N Engl J Med       Date:  2018-09-25       Impact factor: 91.245

6.  EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis.

Authors:  Justin F Gainor; Alice T Shaw; Lecia V Sequist; Xiujun Fu; Christopher G Azzoli; Zofia Piotrowska; Tiffany G Huynh; Ling Zhao; Linnea Fulton; Katherine R Schultz; Emily Howe; Anna F Farago; Ryan J Sullivan; James R Stone; Subba Digumarthy; Teresa Moran; Aaron N Hata; Yukako Yagi; Beow Y Yeap; Jeffrey A Engelman; Mari Mino-Kenudson
Journal:  Clin Cancer Res       Date:  2016-05-25       Impact factor: 12.531

7.  Natural History and Factors Associated with Overall Survival in Stage IV ALK-Rearranged Non-Small Cell Lung Cancer.

Authors:  Jose M Pacheco; Dexiang Gao; Derek Smith; Thomas Purcell; Mark Hancock; Paul Bunn; Tyler Robin; Arthur Liu; Sana Karam; Laurie Gaspar; Brian Kavanagh; Chad Rusthoven; Dara Aisner; Robert Doebele; D Ross Camidge
Journal:  J Thorac Oncol       Date:  2018-12-30       Impact factor: 15.609

8.  Survival by histologic subtype in stage IV nonsmall cell lung cancer based on data from the Surveillance, Epidemiology and End Results Program.

Authors:  Karynsa Cetin; David S Ettinger; Yong-Jiang Hei; Cynthia D O'Malley
Journal:  Clin Epidemiol       Date:  2011-04-28       Impact factor: 4.790

9.  Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy.

Authors:  Ju Yeon Lee; Hyun Tae Lee; Woori Shin; Jongseok Chae; Jaemo Choi; Sung Hyun Kim; Heejin Lim; Tae Won Heo; Kyeong Young Park; Yeon Ji Lee; Seong Eon Ryu; Ji Young Son; Jee Un Lee; Yong-Seok Heo
Journal:  Nat Commun       Date:  2016-10-31       Impact factor: 14.919

10.  An unexpected N-terminal loop in PD-1 dominates binding by nivolumab.

Authors:  Shuguang Tan; Hao Zhang; Yan Chai; Hao Song; Zhou Tong; Qihui Wang; Jianxun Qi; Gary Wong; Xiaodong Zhu; William J Liu; Shan Gao; Zhongfu Wang; Yi Shi; Fuquan Yang; George F Gao; Jinghua Yan
Journal:  Nat Commun       Date:  2017-02-06       Impact factor: 14.919
View more
  4 in total

1.  Network meta-analysis of immune-oncology monotherapy as first-line treatment for advanced non-small-cell lung cancer in patients with PD-L1 expression ⩾50.

Authors:  Nick Freemantle; Yingxin Xu; Florence R Wilson; Patricia Guyot; Chieh-I Chen; Sam Keeping; Gerasimos Konidaris; Keith Chan; Andreas Kuznik; Kokuvi Atsou; Emily Glowienka; Jean-Francois Pouliot; Giuseppe Gullo; Petra Rietschel
Journal:  Ther Adv Med Oncol       Date:  2022-06-16       Impact factor: 5.485

Review 2.  Radiotherapy for non-small cell lung cancer in the immunotherapy era: the opportunity and challenge-a narrative review.

Authors:  Wu-Yan Xia; Wen Feng; Chen-Chen Zhang; Yu-Jia Shen; Qin Zhang; Wen Yu; Xu-Wei Cai; Xiao-Long Fu
Journal:  Transl Lung Cancer Res       Date:  2020-10

3.  Impact of copy number variant and single nucleotide polymorphism of the programmed death-ligand 1 gene, programmed death-ligand 1 protein expression and therapy regimens on overall survival in a large group of Caucasian patients with non-small cell lung carcinoma.

Authors:  Anna Grenda; Paweł Krawczyk; Tomasz Kucharczyk; Justyna Błach; Katarzyna Reszka; Izabela Chmielewska; Jarosław Buczkowski; Robert Kieszko; Jan Siwiec; Tomasz Kubiatowski; Aleksandra Bożyk; Kinga Krukowska; Bożena Jarosz; Iwona Paśnik; Juliusz Pankowski; Daria Świniuch; Katarzyna Stencel; Michał Gil; Kinga Lew; Rodryg Ramlau; Aleksandra Szczęsna; Sebastian Fidler; Andrzej Sieracki; Andrzej Każarnowicz; Piotr Serwatowski; Tomasz Grodzki; Janusz Milanowski
Journal:  Oncol Lett       Date:  2021-04-07       Impact factor: 2.967

4.  A cohort study of the efficacy and safety of immune checkpoint inhibitors plus anlotinib versus immune checkpoint inhibitors alone as the treatment of advanced non-small cell lung cancer in the real world.

Authors:  Yue Shi; Min Ji; Yingying Jiang; Rong Yin; Zihan Wang; Hang Li; Shuaiyu Wang; Kang He; Yuxin Ma; Zhitong Wang; Jianwei Lu; Meiqi Shi; Bo Shen; Guoren Zhou; Tracy L Leong; Xiaohua Wang; Cheng Chen; Jifeng Feng
Journal:  Transl Lung Cancer Res       Date:  2022-06
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.